Agilent Technologies, Inc. (NYSE:A) Shares Sold by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. lowered its position in Agilent Technologies, Inc. (NYSE:A) by 11.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 18,976 shares of the medical research company’s stock after selling 2,476 shares during the period. John G Ullman & Associates Inc.’s holdings in Agilent Technologies were worth $2,638,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. OFI Invest Asset Management acquired a new stake in Agilent Technologies during the 3rd quarter valued at $25,000. Money Concepts Capital Corp acquired a new stake in Agilent Technologies during the 4th quarter valued at $26,000. MV Capital Management Inc. grew its holdings in Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after buying an additional 105 shares during the last quarter. Ancora Advisors LLC acquired a new stake in Agilent Technologies during the 4th quarter valued at $34,000. Finally, Baystate Wealth Management LLC grew its holdings in Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock valued at $36,000 after buying an additional 133 shares during the last quarter.

Agilent Technologies Stock Up 0.2 %

A traded up $0.29 during trading on Friday, hitting $132.73. The company had a trading volume of 1,299,968 shares, compared to its average volume of 1,579,706. The company has a market cap of $38.90 billion, a PE ratio of 31.60, a P/E/G ratio of 4.07 and a beta of 1.11. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58. The business has a 50-day moving average of $141.19 and a 200-day moving average of $129.50. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04.

Agilent Technologies (NYSE:A) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. The company had revenue of $1.66 billion for the quarter, compared to analysts’ expectations of $1.59 billion. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The firm’s revenue was down 5.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 earnings per share. As a group, analysts forecast that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be given a dividend of $0.236 per share. The ex-dividend date of this dividend is Monday, April 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. Agilent Technologies’s dividend payout ratio is currently 22.38%.

Insider Transactions at Agilent Technologies

In other news, SVP Philip Binns sold 2,827 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $147.54, for a total transaction of $417,095.58. Following the completion of the transaction, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares in the company, valued at approximately $7,935,235.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Philip Binns sold 2,827 shares of the firm’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $147.54, for a total transaction of $417,095.58. Following the transaction, the senior vice president now owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The disclosure for this sale can be found here. Over the last quarter, insiders sold 61,610 shares of company stock worth $9,220,333.

Analyst Ratings Changes

A has been the topic of a number of research analyst reports. Barclays raised their price target on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research note on Wednesday, April 10th. Oppenheimer upped their price target on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. Citigroup boosted their price objective on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Evercore ISI boosted their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. Finally, UBS Group lifted their target price on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.